IDEAS home Printed from https://ideas.repec.org/p/ind/igiwpp/2024-023.html
   My bibliography  Save this paper

Individuals social concern, externalities and voluntary vaccination: Monopoly and first-best public policy

Author

Listed:
  • Sumana Kundu

    (Indira Gandhi Institute of Development Research)

  • Rupayan Pal

    (Indira Gandhi Institute of Development Research)

Abstract

This paper studies the role of individuals' social concern in a monopoly vaccine market characterized by externalities, and the first-best public policy. Considering a voluntary vaccination environment and social concern as private information, we show the following. A `spread-preserving, mean-increasing' shift in distribution of social concern induces the monopolist to curb vaccine coverage, unless there is sufficient heterogeneity in social concern. A `mean-preserving, spread-increasing' shift enhances vaccine coverage if vaccine quality and its marginal direct health benefit are sufficiently large. If net intensity of externality is stronger or vaccine quality is higher, for the monopolist to increase vaccine coverage, it's necessary to have significant heterogeneity in social concern. Monopoly-induced downward distortion in market coverage can be corrected through alternative balanced-budget profit-neutral policy interventions. Under endogenous vaccine quality, the monopolist provides a partially-effective vaccine. A performance-linked R&D subsidy that achieves socially optimal vaccine quality depends on the distribution of social concern.

Suggested Citation

  • Sumana Kundu & Rupayan Pal, 2024. "Individuals social concern, externalities and voluntary vaccination: Monopoly and first-best public policy," Indira Gandhi Institute of Development Research, Mumbai Working Papers 2024-023, Indira Gandhi Institute of Development Research, Mumbai, India.
  • Handle: RePEc:ind:igiwpp:2024-023
    as

    Download full text from publisher

    File URL: http://www.igidr.ac.in/pdf/publication/WP-2024-023.pdf
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. d'Aspremont, Claude & Jacquemin, Alexis, 1988. "Cooperative and Noncooperative R&D in Duopoly with Spillovers," American Economic Review, American Economic Association, vol. 78(5), pages 1133-1137, December.
    2. Geoffard, Pierre-Yves & Philipson, Tomas, 1997. "Disease Eradication: Private versus Public Vaccination," American Economic Review, American Economic Association, vol. 87(1), pages 222-230, March.
    3. Reddinger, J. Lucas & Charness, Gary & Levine, David, 2024. "Vaccination as personal public-good provision," Journal of Economic Behavior & Organization, Elsevier, vol. 224(C), pages 481-499.
    4. Upasak Das & Rupayan Pal & Udayan Rathore & Bibhas Saha, 2023. "Rein in pandemic by pricing vaccine: Does social trust matter?," Indira Gandhi Institute of Development Research, Mumbai Working Papers 2023-008, Indira Gandhi Institute of Development Research, Mumbai, India.
    5. Katz, Michael L & Shapiro, Carl, 1985. "Network Externalities, Competition, and Compatibility," American Economic Review, American Economic Association, vol. 75(3), pages 424-440, June.
    6. Hafezi, Maryam & Zhao, Xuan & Zolfagharinia, Hossein, 2023. "Together we stand? Co-opetition for the development of green products," European Journal of Operational Research, Elsevier, vol. 306(3), pages 1417-1438.
    7. Roland Bénabou & Jean Tirole, 2003. "Intrinsic and Extrinsic Motivation," The Review of Economic Studies, Review of Economic Studies Ltd, vol. 70(3), pages 489-520.
    8. Shin-Ae Hong, 2023. "COVID-19 vaccine communication and advocacy strategy: a social marketing campaign for increasing COVID-19 vaccine uptake in South Korea," Palgrave Communications, Palgrave Macmillan, vol. 10(1), pages 1-9, December.
    9. Domenico Buccella & Luciano Fanti & Luca Gori, 2023. "Network externalities, product compatibility and process innovation," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 32(8), pages 1156-1189, November.
    10. F.M. Scherer, 2007. "An industrial organization perspective on the influenza vaccine shortage," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 393-405.
    11. Amir, Rabah, 2000. "Modelling imperfectly appropriable R&D via spillovers," International Journal of Industrial Organization, Elsevier, vol. 18(7), pages 1013-1032, October.
    12. Llanes, Gastón, 2024. "Innovation incentives in technical standards," International Journal of Industrial Organization, Elsevier, vol. 93(C).
    13. Amir, Rabah & Liu, Zhiwei & Tian, Jingwen, 2023. "Negative network effects and public policy in vaccine markets," Journal of Economic Behavior & Organization, Elsevier, vol. 216(C), pages 136-149.
    14. Kessing, Sebastian G. & Nuscheler, Robert, 2006. "Monopoly pricing with negative network effects: The case of vaccines," European Economic Review, Elsevier, vol. 50(4), pages 1061-1069, May.
    15. Patricia Danzon & Nuno Sousa Pereira, 2011. "Vaccine Supply: Effects of Regulation and Competition," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 18(2), pages 239-271.
    16. Phelan, Thomas & Toda, Alexis Akira, 2022. "Optimal epidemic control in equilibrium with imperfect testing and enforcement," Journal of Economic Theory, Elsevier, vol. 206(C).
    17. Alexander W. Cappelen & Trond Halvorsen & Erik Ø. Sørensen & Bertil Tungodden, 2017. "Face-saving or fair-minded: What motivates moral behavior?," Journal of the European Economic Association, European Economic Association, vol. 15(3), pages 540-557.
    18. Meickmann, Felix C., 2023. "Cooperation in knowledge sharing and R&D investment," Journal of Economic Behavior & Organization, Elsevier, vol. 211(C), pages 146-164.
    19. Yang, Jinyu & Zhang, Wenqing & Zhao, Xiande, 2024. "How can suppliers strategically involve downstream manufacturers in research and development collaboration? A knowledge spillover perspective," European Journal of Operational Research, Elsevier, vol. 314(1), pages 122-135.
    20. Jamie Murphy & Frédérique Vallières & Richard P. Bentall & Mark Shevlin & Orla McBride & Todd K. Hartman & Ryan McKay & Kate Bennett & Liam Mason & Jilly Gibson-Miller & Liat Levita & Anton P. Martine, 2021. "Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom," Nature Communications, Nature, vol. 12(1), pages 1-15, December.
    21. Xu, Xiaopeng, 1999. "Technological improvements in vaccine efficacy and individual incentive to vaccinate," Economics Letters, Elsevier, vol. 65(3), pages 359-364, December.
    22. Rabah Amir & Filomena Garcia & Iryna Topolyan, 2023. "First‐best health policy in vaccine markets with health and network externalities," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 25(6), pages 1229-1250, December.
    23. Brito, Dagobert L. & Sheshinski, Eytan & Intriligator, Michael D., 1991. "Externalities and compulsary vaccinations," Journal of Public Economics, Elsevier, vol. 45(1), pages 69-90, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Rabah Amir & Filomena Garcia & Iryna Topolyan, 2023. "First‐best health policy in vaccine markets with health and network externalities," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 25(6), pages 1229-1250, December.
    2. Amir, Rabah & Liu, Zhiwei & Tian, Jingwen, 2023. "Negative network effects and public policy in vaccine markets," Journal of Economic Behavior & Organization, Elsevier, vol. 216(C), pages 136-149.
    3. Stéphane Mechoulan, 2007. "Market structure and communicable diseases," Canadian Journal of Economics/Revue canadienne d'économique, John Wiley & Sons, vol. 40(2), pages 468-492, May.
    4. Buccella, Domenico & Fanti, Luciano & Gori, Luca, 2023. "Optimal R&D disclosure in network industries," Economic Systems, Elsevier, vol. 47(4).
    5. Rikard Forslid & Mathias Herzing, 2015. "On the Optimal Production Capacity for Influenza Vaccine," Health Economics, John Wiley & Sons, Ltd., vol. 24(6), pages 726-741, June.
    6. Kessing, Sebastian G. & Nuscheler, Robert, 2006. "Monopoly pricing with negative network effects: The case of vaccines," European Economic Review, Elsevier, vol. 50(4), pages 1061-1069, May.
    7. Andrea Sorensen, 2023. "The role of vaccine effectiveness on individual vaccination decisions and welfare," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 25(6), pages 1212-1228, December.
    8. Na Hao & Gervan Fearon, 2009. "Government Funding Policy Towards Communicable Diseases," Atlantic Economic Journal, Springer;International Atlantic Economic Society, vol. 37(2), pages 121-134, June.
    9. Sims, Charles & Finnoff, David & O’Regan, Suzanne M., 2016. "Public control of rational and unpredictable epidemics," Journal of Economic Behavior & Organization, Elsevier, vol. 132(PB), pages 161-176.
    10. Andrea Galeotti & Brian W. Rogers, 2013. "Strategic Immunization and Group Structure," American Economic Journal: Microeconomics, American Economic Association, vol. 5(2), pages 1-32, May.
    11. Grunfeld, Leo A., 2003. "Meet me halfway but don't rush: absorptive capacity and strategic R&D investment revisited," International Journal of Industrial Organization, Elsevier, vol. 21(8), pages 1091-1109, October.
    12. Vasileios Zikos, 2010. "R&D Collaboration Networks in Mixed Oligopoly," Southern Economic Journal, John Wiley & Sons, vol. 77(1), pages 189-212, July.
    13. Buccella, Domenico & Fanti, Luciano & Gori, Luca, 2021. "A contribution to the theory of R&D investments," GLO Discussion Paper Series 940, Global Labor Organization (GLO).
    14. Chanel, Olivier & Luchini, Stéphane & Massoni, Sébastien & Vergnaud, Jean-Christophe, 2011. "Impact of information on intentions to vaccinate in a potential epidemic: Swine-origin Influenza A (H1N1)," Social Science & Medicine, Elsevier, vol. 72(2), pages 142-148, January.
    15. Toxvaerd, Flavio, 2010. "Recurrent Infection and Externalities in Prevention," CEPR Discussion Papers 8112, C.E.P.R. Discussion Papers.
    16. Huasheng Song & Vincent Vannetelbosch, 2007. "International R&D Collaboration Networks," Manchester School, University of Manchester, vol. 75(6), pages 742-766, December.
    17. Marie-Laure Cabon-Dhersin & Emmanuelle Taugourdeau, 2015. "Research clusters: How public subsidies matter?," Université Paris1 Panthéon-Sorbonne (Post-Print and Working Papers) hal-01159523, HAL.
    18. Rabah Amir & Raouf Boucekkine, 2023. "Epidemics, vaccines, and health policy," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 25(6), pages 1143-1148, December.
    19. Acemoglu, Daron & Malekian, Azarakhsh & Ozdaglar, Asu, 2016. "Network security and contagion," Journal of Economic Theory, Elsevier, vol. 166(C), pages 536-585.
    20. Helm Carsten & Schöttner Anja, 2008. "Subsidizing Technological Innovations in the Presence of R&D Spillovers," German Economic Review, De Gruyter, vol. 9(3), pages 339-353, August.

    More about this item

    Keywords

    Heterogeneity in social concern; Network externality; Vaccine quality; Monopoly pricing; Social optimality; Public policy;
    All these keywords.

    JEL classification:

    • D91 - Microeconomics - - Micro-Based Behavioral Economics - - - Role and Effects of Psychological, Emotional, Social, and Cognitive Factors on Decision Making
    • D42 - Microeconomics - - Market Structure, Pricing, and Design - - - Monopoly
    • D62 - Microeconomics - - Welfare Economics - - - Externalities
    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ind:igiwpp:2024-023. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Shamprasad M. Pujar (email available below). General contact details of provider: https://edirc.repec.org/data/igidrin.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.